Biotech Archives - Page 94 of 795

1 minute read

Aligos Therapeutics To Host KOL Event To Discuss Phase 2a HERALD Study Of ALG-055009 In MASH On March 7, 2024

February 20, 9:30 AM

Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")))), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that

ALGS

4 minute read

Aemetis Announces Updated 5-Year Plan Projecting Growth To $1.95B Of Revenue And $645M Of Adjusted EBITDA In 2028

By Benzinga Newsdesk

February 20, 9:30 AM

Aemetis, Inc. (NASDAQ:AMTX), a renewable natural gas and renewable fuels company focused on negative carbon intensity products, today announced an updated Aemetis Five Year Plan (the "2024 Plan") that projects the

AMTX

2 minute read

Immuneering Receives FDA Fast Track Designation For IMM-1-104 In Pancreatic Cancer

By Benzinga Newsdesk

February 20, 9:28 AM

– Fast Track designation has the potential to accelerate lead asset IMM-1-104's path to U.S. FDA submission for pancreatic ductal adenocarcinoma – – Company expects multiple readouts from its Phase 1/2a clinical

IMRX

2 minute read

Janux Therapeutics To Host Virtual Event On Monday, February 26th, 2024, At 4:30PM ET To Discuss Updated Clinical Data For PSMA-TRACTr JANX007 And EGFR-TRACTr JANX008

By Benzinga Newsdesk

February 20, 9:27 AM

The virtual event will take place on Monday, February 26th, 2024, at 4:30PM ETJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel

JANX

3 minute read

ProPhase Labs Announces Progress In BE-Smart Esophageal Cancer Test Development USPTO Grants Additional Broad Patents For BE-SMART

By Happy Mohamed

February 20, 9:19 AM

ProPhase Labs, Inc. (NASDAQ:PRPH), a next generation biotech, genomics and diagnostics company, today announced important developments in the Company's efforts to commercialize its novel

PRPH

2 minute read

60 Degrees Pharmaceuticals To Sponsor Pre-Clinical Studies Of Tafenoquine Use In Candida spp, Including Candida auris

By Benzinga Newsdesk

February 20, 9:09 AM

Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitalsTafenoquine's presumed mode of action against C. auris is differentiated from standard of care treatmentMonash University

SXTP

4 minute read

Tharimmune Announces Results In Phase 1 Clinical Trial Of TH104, Compared Oral Transmucosal Delivery Of TH104 To Injectable Reference Approved Drug Completed

By Benzinga Newsdesk

February 20, 9:08 AM

Positive safety/tolerability profile achieved with TH104 showing self-resolving, mild side effect profile aligned with previous studiesPhase 1 clinical trial compared oral transmucosal delivery of TH104 to injectable

THAR

2 minute read

IGC Pharma Announces Q3 2024 Earnings: Strategic Patent Achievements Propel Forward Amid Losses

By Patricio Liddle

February 19, 2:17 PM

IGC Pharma's Q3 2024 results: Navigating financial dips with strategic patents in pain treatment and Alzheimer's therapy.

IGC

1 minute read

Iovance Biotherapeutics to Host Conference Call And Webcast On Friday, February 16, 2024 At 4:15 p.m. ET, To Discuss The FDA Approval

By Benzinga Newsdesk

February 16, 4:40 PM

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a

IOVA

6 minute read

Iovance’s AMTAGVI Receives U.S. FDA Accelerated Approval For Advanced Melanoma

By Benzinga Newsdesk

February 16, 4:22 PM

AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy AMTAGVI deploys patient-specific immune cells that

IOVA